Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 2569

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 2569
---
910 during the year ended December 31, 2023). The Company’s capital commitments
over the next twelve months include interest payments on the Company’s debt arrangements of $8,772 and $1,007,618 to satisfy accounts
payable and accrued expenses.

To date, the Company has funded its operations primarily with proceeds
from sales of common stock and warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible
debt and borrowings under loan and security agreements.

Continuation as a going concern is dependent upon the Company’s
ability to meet its financial requirements, raise additional capital, and achieve gross profitability from the Company’s single
marketed product. To achieve profitability, the Company expects it will need to raise additional capital to fund its activities relating
to commercial support for its existing product and any future clinical research trials and operating activities. However, there can be
no assurance that it will ever achieve or maintain profitability. These conditions, among others, raise substantial doubt about the
ability of the Company to continue as a going concern for one year from the date these financial statements are issued.

Management plans to fund operations of the Company
through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent
offering until such a time as the business achieves profitability or a business combination may be achieved. However, there can be no
assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that
are favorable to the Company. Debt financing and equity financing, if available, may involve agreements that include covenants limiting
or restricting the Company’s ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends. If the Company raises funds through collaborations, or other similar arrangements with third parties, it may have
to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on
terms that may not be favorable to the Company and/or may reduce the value of its common stock. If the Company is unable to raise additional
funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or
future commercialization efforts or grant rights to develop and market its product candidates even if the Company would otherwise prefer
to develop and market such product candidates itself.

As such, management concluded that such plans
do not alleviate the